関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 3-methoxy-1-methyl-1H-pyrazol-5-amine | HCID 55284552 | — |
| 反応物 | 2-(2-Chloro-5-cyanopyridin-4-ylamino)-N-methylbenzamide | HCID 57516913 | — |
| 試薬 | Cesium carbonate | HCID 10796 | — |
| 触媒 | 1,1'-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(1,1-diphenylphosphine) | HCID 636044 | — |
| 触媒 | Palladium (II) acetate | HCID 4144353 | — |
| 溶媒 | 1,4-Dioxane | HCID 31275 | — |
| 生成物 | 2-[[5-cyano-2-[(3-methoxy-1-methylpyrazol-5-yl)amino]-4-pyridinyl]amino]-N-methylbenzamide | HCID 44609198 | 54.7% |
反応手順
2-(2-chloro-5-cyanopyridin-4-ylamino)-N-methylbenzamide (100 mg, 0.35 mmol), Palladium(II) acetate (6.26 mg, 0.03 mmol), [Reactants], 9,9-Dimethyl-4,5-bis(diphenylphosphino)xanthene (24.22 mg, 0.04 mmol) and Cesium carbonate (136 mg, 0.42 mmol) were suspended in dioxane (3 mL) into a test tube. The reaction was purged for 5 mins with nitrogen and then heated to 90 °C for 18 hours with stirring. The reaction was cooled to cooled to RT. The crude product was purified by ion exchange chromatography, using an SCX column. The desired crude product was eluted from the column using 7M NH3/MeOH and fractions were evaporated to dryness to afford crude product .The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5µ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 2-(5-cyano-2-(3-methoxy-1-methyl-1H-pyrazol-5-ylamino)pyridin-4-ylamino)-N-methylbenzamide (72.0 mg, 54.7 %) as a beige solid.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-d012fdccb17647d4838efd4e1491311e |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|